Home LiteratureArticle Details
PMID: 19621457 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Natural history and outcome of optic pathway gliomas in children.

Pediatric blood & cancer ·Vol. 53 ·No. 7 ·2009-12-15 ·页码 1231-7

Nicolin G, Parkin P, Mabbott D, Hargrave D, Bartels U, Tabori U, Rutka J, Buncic JR, Bouffet E

Abstract

The optimal management of optic pathway gliomas (OPGs) is complicated by their variable natural history, the association with neurofibromatosis type 1 (NF1) and difficulties in defining progression and response to treatment. This study is a retrospective review of all children presenting to a single institution with an OPG between 1990 and 2004. Of the 133 children included, 78 (59%) had NF1; 87 (71 NF1) were observed initially, of whom 23 (11 NF1) subsequently required treatment. Forty-six patients received immediate treatment. Initial treatment, without or with an observation period, comprised chemotherapy alone (32, 11 NF1); debulking + chemotherapy (15, 4 NF1); gross total resection (6); radiotherapy (2); debulking + radiotherapy (3); and debulking only (12, 3 NF1). Overall, 16 patients were irradiated during the study period. Four children died (overall survival at 5 and 10 years was 97.6% and 94.6% for those who required treatment). Progression-free survival (PFS) for the 69 patients who needed treatment was 48%. There was no difference in PFS between chemotherapy versus chemotherapy + debulking or debulking alone. PFS for the NF1 patients who required treatment was similar to that of non-NF1 patients. Mean follow-up time was 9.0 (range 0.6-18.0, median 8.6) years. The study confirms the complexity of OPGs and that NF1 is a major determinant of the resultant behavior of the tumor.

MeSH 主题词
Adolescent Antineoplastic Combined Chemotherapy Protocols/adverse effects,therapeutic use Brain Damage, Chronic/etiology Carboplatin/administration & dosage Child Child, Preschool Combined Modality Therapy Cranial Irradiation/adverse effects Disease Progression Disease-Free Survival Female Follow-Up Studies Humans Infant Intellectual Disability/etiology Lomustine/administration & dosage Male Neurofibromatosis 1/epidemiology Optic Nerve Glioma/complications,drug therapy,epidemiology,pathology,radiotherapy,surgery Procarbazine/administration & dosage Retrospective Studies Survival Analysis Thioguanine/administration & dosage Treatment Outcome Vinblastine/administration & dosage Vincristine/administration & dosage Vision Disorders/etiology
化学物质
Procarbazine Vincristine Vinblastine Lomustine Carboplatin Thioguanine
作者与单位
共 9 位作者,点击展开单位 / ORCID
Nicolin Gary
Pediatric Brain Tumor Program, Division of Hematology/Oncology, Hospital for Sick Children, Toronto, Ontario, Canada.
Parkin Patricia
Mabbott Donald
Hargrave Darren
Bartels Ute
Tabori Uri
Rutka James
Buncic J Raymond
Bouffet Eric
Article Info
Journal
Pediatric blood & cancer
Abbr.
Pediatr Blood Cancer
ISSN
1545-5017
Published
2009-12-15
页码
1231-7
Language
English
Country/Region
United States
NLM ID
101186624
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com